Amolyt Pharma has recently announced that they have dosed the first patient in their trial of AZP-3601, a treatment for hypoparathyroidism. According to GlobeNewswire, this treatment will adequately address the various symptoms of the condition. As this is something that current therapies fail to do, medical professionals and patients are very excited about the developments of AZP-3601.
About Hypoparathyroidism
Hypoparathyroidism is a condition that is characterized by a lack of parathyroid hormone (PTH). This hormone is necessary for controlling levels of calcium and phosphorus. When there are abnormal amounts of either in the body, affected individuals experience symptoms like muscle aches and cramps, tingling and burning sensations, weakness, fatigue, dry and coarse skin, brittle nails, twitching and spasms, depression, anxiety, hair loss, and painful menstruation. Complications may also arise from this condition, such as arrhythmias, issues with kidney function, and fainting. All of these are due to the four parathyroid glands secreting low levels of PTH. They can do so for a multitude of reasons, such as an autoimmune disorder, a surgery, cancer treatments, low levels of magnesium in the blood, and a hereditary form of hypoparathyroidism. Treatments aim to regulate levels of calcium and phosphorus.
About AZP-3601
AZP-3601 is a peptide that targets PTH receptors with the intention of producing normal amounts of calcium, therefore treating the cause of symptoms. It promotes the reabsorption of calcium into the kidneys, maintaining calcium levels and even preventing chronic kidney disease. It has also shown to help with bone integrity, therefore lowering the risk of osteoporosis.
About the Trial
This trial will evaluate the tolerability, safety, pharmacodynamics, pharmacokinetics, and initial efficacy of AZP-3601. Researchers have enrolled healthy participants as well as those with hypoparathyroidism, all of whom will receive either single or multiple ascending doses. Healthy patients will be treated as a single group, whereas hypoparathyroidism patients are being evaluated at multiple sites across Europe.
As the first participant has officially been dosed, researchers are looking forward and are very excited. If this trial and subsequent studies are successful, this could present a new, viable treatment option to those with hypoparathyroidism, one that actually addresses all of their symptoms.
